VCYT NASDAQ
Veracyte, Inc.
1W: +12.3%
1M: +11.2%
3M: -9.8%
YTD: +18.6%
1Y: +36.9%
3Y: +140.2%
5Y: +7.4%
$50.28
+2.08 (+4.32%)
Weekly Expected Move ±6.8%
$41
$45
$48
$51
$54
Credit Risk of going bust: lower than 73% of companies Debt: 1.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99.9%), Veracyte, Inc. would be worth roughly what it owes.
Total debt $40.1M against a stock market value of $4.04B.
Distance to default 8.06 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $20.1M (short-term plus half of long-term), stock volatility 64.2%; Altman Z'' 16.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.07 (down 99.9%), Veracyte, Inc. would be worth roughly what it owes.
Total debt $40.1M against a stock market value of $4.04B.
Distance to default 8.06 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $20.1M (short-term plus half of long-term), stock volatility 64.2%; Altman Z'' 16.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2021-06-01
Earliest Filing
2024-02-06
Latest Filing
target: 5
Counterparties (Filed by VCYT)
5 relationshipsCompanies named in VCYT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| C2i Genomics, Inc. | — | target | Acquired by Veracyte, Inc. for $70.0 million in stock and cash consideration. | 2024-02-06 | View |
| HalioDx SAS | — | target | Acquired by Veracyte, Inc. for €260 million in cash and stock. | 2021-08-03 | View |
| HalioDx SAS | — | target | Target company acquired by Veracyte, Inc. in a securities purchase and contribution agreement. | 2021-07-13 | View |
| HalioDx SAS | — | target | Target company acquired by Veracyte, Inc. for €260 million in cash and stock. | 2021-06-08 | View |
| HalioDx SAS | — | target | Target company acquired by Veracyte, Inc. for €260 million in cash and stock. | 2021-06-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-14 | Material Agreement; Acquisition/Disposition; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-06-11 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-03-16 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-18 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-04 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-13 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2024-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-04-17 | Financial Statements and Exhibits | View | |
| 2024-03-22 | Other Events; Financial Statements and Exhibits | View | |
| 2024-02-29 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR